[1] Holdhoff M, Yovino SG, Boadu O, et al. Blood-based biomarkers for malignant gliomas[J].J Neurooncol,2013,113(3): 345-352.
[2] Perera M, Papa N, Christidis D, et al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis[J]. Eur Urol,2016,70(6): 926-937.
[3] Kurahashi T, Miyake H, Shinozaki M, et al. Screening for prostate cancer using prostate-specific antigen testing in Japanese men on hemodialysis[J]. Int Urol Nephrol,2008,40(2): 345-349.
[4] Bruun L, Savage C, Cronin AM, et al. Increase in percent free prostate-specific antigen in men with chronic kidney disease[J]. Nephrol Dial Transplant,2009,24(4): 1238-1241.
[5] Joseph DA. Association Between Glomerular Filtration Rate, Free, Total, and Percent Free Prostate-specific Antigen REPLY[J]. Urology,2010,76(5): 1047-1047.
[6] Chen CJ, Heldt JP, Anderson KM, et al. Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease[J]. J Urol,2012,187(6): 2061-2065.
[7] Xiaofang Y, Yue Z, Xialian X, et al. Serum tumour markers in patients with chronic kidney disease[J]. Scand J Clin Lab Invest,2007,67(6): 661-667.
[8] Maoujoud O, El Machtani S, Asseraji M, et al. Serum tumor markers in hemodialysis patients[J]. Int J Artif Organs,2014,37(2): 126-132.
[9] Tzanakis I, Kazoulis S, Girousis N, et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels[J]. Nephron,2002,90(2): 230-233.
[10] Sasagawa I, Kubota Y, Hayami S, et al. Serum levels of total and free prostate specific antigen in men on hemodialysis[J]. J Urol,1998,160(1): 83-85.
[11] Djavan B, Shariat S, Ghawidel K, et al. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis?[J]. Urology,1999,53(6): 1169-1174.
[12] Arik N, Adam B, Akpolat T, et al. Serum tumour markers in renal failure[J]. Int Urol Nephrol,1996,28(4): 601-604.
[13] Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications[J]. Clin Chim Acta,2008,395(1-2): 19-26.
[14] Toyoda H, Hiraoka A, Tada T, et al. Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis[J]. Ther Apher Dial,2017,21(5): 465-472.
[15] Tong HL, Dong ZN, Wen XY, et al. Impact of chronic kidney disease on serum tumor markers concentrations[J]. Chinese Medical Journal,2013,126(2): 274-279.
[16] Zeferos N, Digenis GE, Christophoraki M, et al. Tumor markers in patients undergoing hemodialysis or kidney transplantation[J]. Nephron,1991,59(4): 618-620.
[17] Tzitzikos G, Saridi M, Filippopoulou T, et al. Measurement of tumor markers in chronic hemodialysis patients[J]. Saudi J Kidney Dis Transpl,2010,21(1): 50-53.
[18] Huang YQ, Liang CH, He L, et al. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer[J]. J Clin Oncol,2016,34(18): 2157-2164.
[19] Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer[J]. Lung Cancer,2012,76(2): 138-143.
[20] Sorensen CG, Karlsson WK, Pommergaard HC, et al. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review[J]. Int J Surg,2016,25(1): 134-144.
[21] Rani BS, Suchitra MM, Srinivasa Rao P, et al. Serum tumor markers in advanced stages of chronic kidney diseases[J]. Saudi J Kidney Dis Transpl,2019,30(4): 898-904.
[22] Yu X, Xu X, Ye Z. Effect of renal function and hemodialysis on the serum tumor markers in patients with chronic kidney disease[J]. Front Med China,2007,1(3): 308-311.
[23] Mikkelsen G, Asberg A, Hultstrom ME, et al. Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease[J]. Int J Biol Markers,2017,32(4): e461-e466.
[24] Estakhri R, Ghahramanzade A, Vahedi A, et al. Serum levels of CA15-3, AFP, CA19-9 and CEA tumor markers in cancer care and treatment of patients with impaired renal function on hemodialysis[J]. Asian Pac J Cancer Prev,2013,14(3): 1597-1599.
[25] Polenakovic M, Sikole A, Dzikova S, et al. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients[J]. Int J Artif Organs,1997,20(2): 96-100.
[26] Chen J, Tao F, Zhang B, et al. Elevated Squamous Cell Carcinoma Antigen, Cytokeratin 19 Fragment, and Carcinoembryonic Antigen Levels in Diabetic Nephropathy[J]. Int J Endocrinol,2017,2017: 5304391.
[27] Menzin AW, Kobrin S, Pollak E, et al. The effect of renal function on serum levels of CA 125[J]. Gynecol Oncol,1995,58(3): 375-377.
[28] Sevinc A, Buyukberber S, Sari R, et al. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids[J]. Gynecol Oncol,2000,77(2): 254-257.
[29] Han SN, Lotgerink A, Gziri MM, et al. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review[J]. Bmc Medicine,2012,10(1): 86.
[30] Peng YF, Lin H, Han MM, et al. Serum carbohydrate antigen 153 and renal function in patients with type 2 diabetes mellitus[J]. J Clin Lab Anal,2018,32(7): e22461.
[31] Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population[J]. J Gastroenterol Hepatol,2004,19(2): 182-186.
[32] Fukasawa H, Kaneko M, Niwa H, et al. Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease[J]. Nephrology (Carlton),2018,23(3): 210-216.
